Literature DB >> 9472655

Early increase of CD4+ CD45RA+ and CD4+ CD95- cells with conserved repertoire induced by anti-retroviral therapy in HIV-infected patients.

G Silvestri1, C Munoz-Calleja, P Bagnarelli, G Piedimonte, M Clementi, M Montroni.   

Abstract

Administration of anti-retroviral drugs induces a decrease of viral load associated with increase of CD4+ cell count in most HIV-infected patients. To investigate the early changes in CD4+ cell phenotype induced by anti-retroviral therapy, six patients with CD4+ cell count > 100/mm3 and never treated with anti-HIV therapy were enrolled and blood samples collected several times within 14 days from the initiation of therapy with Zidovudine plus Didanosine. CD4+ cell count and HIV viraemia were investigated at each time point, as well as the expression of CD45RA, CD45RO and CD95/Fas molecules on CD4+ cells, and the T cell receptor (TCR) Vbeta repertoire of CD4+ cells. All patients showed a rapid and dramatic decrease in viral load with a corresponding increase of CD4+ cell count. The main remodelling of CD4+ cell subpopulations took place in the first 14 days of therapy, and consisted of: (i) increased CD4+CD45RA+/CD4+CD45RO+ ratio; (ii) decrease of CD95/Fas expression. The rise in absolute number of CD4+CD45RA+ cells was paralleled by an increase of CD4+CD95/Fas- cells and accounted for most of the early increment of CD4+ cell count. The TCR Vbeta repertoire of CD4+ cells was conserved after anti-HIV therapy, with the exception of two patients with expanded CD4+Vbeta12+ cells, which also tested CD45RA+ and CD95/Fas-. These experiments show that newcomer CD4+ lymphocytes are CD45RA+CD95/Fas- cells, suggesting that blocking HIV replication causes an early and antigen-independent proliferation of possibly 'naive' cells unprimed for CD95/Fas-mediated apoptosis. These cells expressed a conserved and widespread TCR repertoire, suggesting that their capability for antigenic recognition is intact.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9472655      PMCID: PMC1904844          DOI: 10.1046/j.1365-2249.1998.00464.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  56 in total

Review 1.  Lymphocyte life-span and memory.

Authors:  J Sprent; D F Tough
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

2.  T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects.

Authors:  M T Roos; F Miedema; M Koot; M Tersmette; W P Schaasberg; R A Coutinho; P T Schellekens
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

3.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

4.  Infection frequency of dendritic cells and CD4+ T lymphocytes in spleens of human immunodeficiency virus-positive patients.

Authors:  D McIlroy; B Autran; R Cheynier; S Wain-Hobson; J P Clauvel; E Oksenhendler; P Debré; A Hosmalin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

5.  Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden.

Authors:  C A Muro-Cacho; G Pantaleo; A S Fauci
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

6.  Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.

Authors:  M O Westendorp; R Frank; C Ochsenbauer; K Stricker; J Dhein; H Walczak; K M Debatin; P H Krammer
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

7.  Massive activation of immune cells with an intact T cell repertoire in acute human immunodeficiency virus syndrome.

Authors:  A Cossarizza; C Ortolani; C Mussini; V Borghi; G Guaraldi; N Mongiardo; E Bellesia; M G Franceschini; B De Rienzo; C Franceschi
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

8.  Human immunodeficiency virus 1 reservoir in CD4+ T cells is restricted to certain V beta subsets.

Authors:  D Dobrescu; S Kabak; K Mehta; C H Suh; A Asch; P U Cameron; A S Hodtsev; D N Posnett
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

9.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  Turnover of naive- and memory-phenotype T cells.

Authors:  D F Tough; J Sprent
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  4 in total

1.  Induction of CD95 ligand expression on T lymphocytes and B lymphocytes and its contribution to apoptosis of CD95-up-regulated CD4+ T lymphocytes in macaques by infection with a pathogenic simian/human immunodeficiency virus.

Authors:  Y Sasaki; Y Ami; T Nakasone; K Shinohara; E Takahashi; S Ando; K Someya; Y Suzaki; M Honda
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery.

Authors:  A E Sousa; A F Chaves; M Doroana; F Antunes; R M Victorino
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation.

Authors:  Mark A Wallet; Caroline M Reist; Julie C Williams; Sofia Appelberg; Giorgio L Guiulfo; Brent Gardner; John W Sleasman; Maureen M Goodenow
Journal:  J Leukoc Biol       Date:  2012-07-11       Impact factor: 4.962

Review 4.  Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era.

Authors:  Emily Adland; Paul Klenerman; Philip Goulder; Philippa C Matthews
Journal:  Front Microbiol       Date:  2015-09-24       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.